The current status of COVID-19 vaccines. A scoping review

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new disease that has led to a worldwide pandemic, resulting in millions of deaths and a high economic burden. Here, we analyze the current status of preventive vaccines authorized by the European Medicines Agency (EMA) and the US Food...

Descripción completa

Detalles Bibliográficos
Autores principales: Rueda-Fernández, Manuel, Melguizo-Rodríguez, Lucía, Costela-Ruiz, Víctor J., González-Acedo, Anabel, Ramos-Torrecillas, Javier, Illescas-Montes, Rebeca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Post-Screen (Grey)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389839/
https://www.ncbi.nlm.nih.gov/pubmed/35995361
http://dx.doi.org/10.1016/j.drudis.2022.08.004
_version_ 1784770543714566144
author Rueda-Fernández, Manuel
Melguizo-Rodríguez, Lucía
Costela-Ruiz, Víctor J.
González-Acedo, Anabel
Ramos-Torrecillas, Javier
Illescas-Montes, Rebeca
author_facet Rueda-Fernández, Manuel
Melguizo-Rodríguez, Lucía
Costela-Ruiz, Víctor J.
González-Acedo, Anabel
Ramos-Torrecillas, Javier
Illescas-Montes, Rebeca
author_sort Rueda-Fernández, Manuel
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new disease that has led to a worldwide pandemic, resulting in millions of deaths and a high economic burden. Here, we analyze the current status of preventive vaccines authorized by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Published clinical trials have shown the effectiveness of mRNA (BNT162b2 and Spikevax), adenovirus vector-based (Ad26.COV2.S and ChAdOx1 nCoV-19), and recombinant protein S (NVX-CoV2373) vaccines to be between 52.9% and 100%. The most-frequent adverse effects include local pain, fatigue, headache, or chills. Serious events are associated with Ad26.COV2.S and ChAdOx1 nCoV-19 vaccines.
format Online
Article
Text
id pubmed-9389839
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-93898392022-08-19 The current status of COVID-19 vaccines. A scoping review Rueda-Fernández, Manuel Melguizo-Rodríguez, Lucía Costela-Ruiz, Víctor J. González-Acedo, Anabel Ramos-Torrecillas, Javier Illescas-Montes, Rebeca Drug Discov Today Post-Screen (Grey) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new disease that has led to a worldwide pandemic, resulting in millions of deaths and a high economic burden. Here, we analyze the current status of preventive vaccines authorized by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Published clinical trials have shown the effectiveness of mRNA (BNT162b2 and Spikevax), adenovirus vector-based (Ad26.COV2.S and ChAdOx1 nCoV-19), and recombinant protein S (NVX-CoV2373) vaccines to be between 52.9% and 100%. The most-frequent adverse effects include local pain, fatigue, headache, or chills. Serious events are associated with Ad26.COV2.S and ChAdOx1 nCoV-19 vaccines. Elsevier Ltd. 2022-11 2022-08-19 /pmc/articles/PMC9389839/ /pubmed/35995361 http://dx.doi.org/10.1016/j.drudis.2022.08.004 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Post-Screen (Grey)
Rueda-Fernández, Manuel
Melguizo-Rodríguez, Lucía
Costela-Ruiz, Víctor J.
González-Acedo, Anabel
Ramos-Torrecillas, Javier
Illescas-Montes, Rebeca
The current status of COVID-19 vaccines. A scoping review
title The current status of COVID-19 vaccines. A scoping review
title_full The current status of COVID-19 vaccines. A scoping review
title_fullStr The current status of COVID-19 vaccines. A scoping review
title_full_unstemmed The current status of COVID-19 vaccines. A scoping review
title_short The current status of COVID-19 vaccines. A scoping review
title_sort current status of covid-19 vaccines. a scoping review
topic Post-Screen (Grey)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389839/
https://www.ncbi.nlm.nih.gov/pubmed/35995361
http://dx.doi.org/10.1016/j.drudis.2022.08.004
work_keys_str_mv AT ruedafernandezmanuel thecurrentstatusofcovid19vaccinesascopingreview
AT melguizorodriguezlucia thecurrentstatusofcovid19vaccinesascopingreview
AT costelaruizvictorj thecurrentstatusofcovid19vaccinesascopingreview
AT gonzalezacedoanabel thecurrentstatusofcovid19vaccinesascopingreview
AT ramostorrecillasjavier thecurrentstatusofcovid19vaccinesascopingreview
AT illescasmontesrebeca thecurrentstatusofcovid19vaccinesascopingreview
AT ruedafernandezmanuel currentstatusofcovid19vaccinesascopingreview
AT melguizorodriguezlucia currentstatusofcovid19vaccinesascopingreview
AT costelaruizvictorj currentstatusofcovid19vaccinesascopingreview
AT gonzalezacedoanabel currentstatusofcovid19vaccinesascopingreview
AT ramostorrecillasjavier currentstatusofcovid19vaccinesascopingreview
AT illescasmontesrebeca currentstatusofcovid19vaccinesascopingreview

Ejemplares similares